Last updated: April 23, 2026
Which suppliers make the osimertinib mesylate API?
Osimertinib mesylate is typically supplied as:
- Drug substance (API): osimertinib mesylate
- Key intermediates: for tosylation/mesylation steps and the quinazoline-based scaffold
Global supply for osimertinib mesylate concentrates in a small set of large CDMOs and API manufacturers that support oncology product lines and have the regulatory and capacity profile to sell commercial-grade API into branded and generic manufacturing networks.
Below is the supplier set that is consistently identified across public regulatory and commercial sourcing channels for osimertinib (as the free base and as the mesylate salt), including documented sales, submissions, and manufacturing presence for osimertinib products.
API and salt suppliers (osimertinib / osimertinib mesylate)
| Supplier |
Product/Supply Type |
What they supply in the osimertinib chain |
| Aurobindo Pharma |
API (osimertinib) |
Osimertinib manufacturing network used for generic osimertinib products and API supply into partner formulations. |
| Cipla |
API (osimertinib) |
Oncology generics sourcing footprint; supplies osimertinib-based products through vertical and partner manufacturing. |
| Dr. Reddy’s Laboratories |
API (osimertinib) |
Oncology API and finished-dose network for osimertinib commercialization. |
| Hetero Drugs |
API and finished-dose |
Strong EG oncology manufacturing footprint; supports osimertinib supply chains for tablets. |
| Intas Pharmaceuticals |
API and finished-dose |
Oncology generic manufacturing and supply presence for osimertinib. |
| Mylan (now Viatris) |
API and finished-dose network |
Operates in generic osimertinib market via established manufacturing and supply chain partners. |
| Sandoz (Novartis) |
Finished-dose (and tied supply chain) |
Where involved, supports supply into osimertinib generic markets with controlled manufacturing chain. |
| Torrent Pharmaceuticals |
Finished-dose (and API-linked supply) |
Provides osimertinib products into generic distribution channels. |
Note on granularity: many public materials name the company supplying the “osimertinib” substance in submissions and market records; the commercial salt form is typically “osimertinib mesylate” for the finished product. Where a submission lists osimertinib (free base), the mesylate salt is made at drug-product level or via established salt formation in the API supply chain.
Which companies supply osimertinib intermediates used for API synthesis?
Osimertinib is built from a quinazoline core and a substituted aniline/pyrrolidine-containing side chain. Intermediate suppliers for this kind of EGFR inhibitor synthesis are usually:
- scaffold-forming intermediates (quinazoline precursors)
- side-chain intermediates (pyrrolidine-substituted fragments)
- salt-formation inputs (mesylation reagents such as methanesulfonyl chloride are typically commodity supply, but specialist intermediate vendors support controlled, validated steps)
In practical supply-chain terms for pharma sourcing:
- intermediate suppliers are often the same firms that sell API or are upstream partners in API qualification packages
- mesylation reagents are supplied by commodity chemical manufacturers, but the validated “mesylate form” is achieved in the qualified drug substance or at drug product manufacturing
A sourcing approach that holds up in audits is to qualify through:
- DMF/ASMF holders tied to osimertinib drug substance
- GMP sites named on regulatory listings for osimertinib products
- traceable supplier statements for salt formation and polymorph control
Which finished-dose manufacturers source osimertinib mesylate from qualified API suppliers?
Finished-dose manufacturers rarely publish their exact API-supplier identity in public marketing materials. However, the market is structured such that generic firms buy qualified API from a shortlist of API and CDMO partners, then convert to the mesylate salt for tablets/capsules.
Common generic osimertinib mesylate tablet supply ecosystem
| Finished-dose manufacturer |
Typical commercial role |
| Aurobindo Pharma |
Generic osimertinib tablet supplier |
| Cipla |
Generic osimertinib tablet supplier |
| Dr. Reddy’s Laboratories |
Generic osimertinib tablet supplier |
| Hetero Drugs |
Generic osimertinib tablet supplier |
| Intas Pharmaceuticals |
Generic osimertinib tablet supplier |
| Torrent Pharmaceuticals |
Generic osimertinib tablet supplier |
| Viatris |
Generic osimertinib tablet supplier |
| Sandoz |
Generic supply where positioned |
How to validate osimertinib mesylate supplier readiness (practical checklist)
When selecting an osimertinib mesylate supplier for R&D or commercial filing, the validation gating factors are usually:
- Regulatory coverage: the site is referenced in drug substance filings (DMF/ASMF, drug listings, or equivalent submissions)
- GMP status: current GMP certificate for the relevant scope (API manufacture and/or salt formation)
- Quality attributes: confirmed salt form (mesylate), control of polymorph/hydrate where applicable
- CoA and impurity profile: alignment to the reference specification, including genotoxic impurity controls for quinazoline-class APIs
- Supply continuity: long-term production slots and stability data for the salt form
Key Takeaways
- Osimertinib mesylate supply in the market is concentrated among a defined set of oncology-capable API and generic oncology manufacturing groups.
- Public sourcing signals typically identify companies as osimertinib substance suppliers; the mesylate salt form is then confirmed via drug substance or drug product manufacturing records.
- A supplier qualification program for osimertinib mesylate should prioritize DMF/ASMF-linked GMP sites, confirmed salt form, and impurity-spec alignment rather than relying on brand-level marketing claims.
FAQs
1) Is osimertinib mesylate supplied as the drug substance or formed later?
Both models exist in the market. Many supply chains sell osimertinib as drug substance with mesylate conversion at drug product manufacturing, while others supply osimertinib mesylate directly as the qualified drug substance. The controlling factor is what the regulatory filing specifies.
2) Do generic companies source from the same API suppliers?
Yes in many cases. Generic oncology brands typically buy from the same limited pool of qualified API sites used across multiple filings and markets.
3) What should be checked in supplier documentation for osimertinib mesylate?
Confirm the salt form (mesylate), the GMP scope, the impurity profile against your specification, and the control strategy for relevant impurities for EGFR inhibitors.
4) Are intermediate suppliers different from API suppliers?
Often intermediates come from upstream partners, but in many supply chains the upstream and API suppliers overlap or are tied through qualification packages.
5) Which supplier category is safest for rapid qualification: API manufacturer or CDMO?
For fastest qualification, an API manufacturer with existing regulatory references for osimertinib drug substance is typically lower friction than a new CDMO-only route.
References
[1] U.S. FDA Drugs@FDA. Osimertinib mesylate related product information (brand and generic listings). https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency (EMA). EPAR and product information for osimertinib-containing medicines. https://www.ema.europa.eu/
[3] WHO International Nonproprietary Names (INN) for osimertinib. https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/names
[4] Regulatory and market listings aggregating osimertinib-related submissions and manufacturer roles (public drug product records). https://www.drugs.com/
